Skip to main content
Fig. 6 | Acta Neuropathologica Communications

Fig. 6

From: Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease

Fig. 6

Immunodepletion of tau seeds with E2814 reduces intracellular tau deposition. E2814 antibody or human IgG1 control at specified concentrations were used to immunodeplete K18 fibrils (a,b) or full length P301S tau monomer (c,d) seeds. Treated samples were added to HEK293 cells overexpressing P301S mutant 0N4R tau. Intracellular tau deposition was measured by addition of Thioflavin S (ThS) and cells were counterstained with DAPI to visualise the nuclei. The percentage of ThS/DAPI relative to IgG1 control is plotted (IgG1 = 100% seeding effect). Values represent the mean ± SEM from four (a) and three (c) independent experiments. Data were analysed by one way ANOVA followed by Dunnett’s test. *P < 0.05, **P < 0.005, **** < 0.0001. Representative images of ThS and DAPI staining for K18 fibril (B, 3 μg antibody) and P301S monomer (d, 10 μg antibody) immunodepleted seeds are shown. Scale bars = 200 μm

Back to article page
\